AstraZeneca (LON:AZN) Rating Reiterated by Liberum Capital

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by stock analysts at Liberum Capital in a research report issued to clients and investors on Wednesday, August 7th, ThisIsMoney.Co.Uk reports.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 25th. Citigroup reissued a “buy” rating and issued a GBX 7,000 ($91.47) price target on shares of AstraZeneca in a research report on Monday, May 13th. Kepler Capital Markets set a GBX 6,470 ($84.54) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Monday, May 13th. Finally, UBS Group reiterated a “sell” rating and set a GBX 5,400 ($70.56) price target on shares of AstraZeneca in a research note on Thursday, July 25th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of GBX 6,688.24 ($87.39).

AstraZeneca stock opened at GBX 7,299 ($95.37) on Wednesday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The stock has a market cap of $94.85 billion and a price-to-earnings ratio of 42.63. The firm has a 50 day simple moving average of GBX 6,755.80 and a 200-day simple moving average of GBX 6,227.49. AstraZeneca has a 1-year low of GBX 5,312 ($69.41) and a 1-year high of GBX 7,349.30 ($96.03).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Stop Order

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.